Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION(R) Platform at the European Society of Medical Oncology Annual Congress
(LSE – AIM:AVCT), Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m(2) (approximately 4x conventional […]